Skip to main content
B&K CORPORATION LIMITED logo

B&K CORPORATION LIMITED — Investor Relations & Filings

Ticker · 2396 HKEX Manufacturing
Open in API
Filings indexed 34 across all filing types
Latest filing 2026-04-29 Regulatory Filings
Country HK Hong Kong
Listing HKEX 2396

About B&K CORPORATION LIMITED

https://huarenshengwu.com

B&K Corporation Limited operates as an innovative biopharmaceutical company specializing in the discovery, development, and commercialization of systematic and integrated biomacromolecule therapeutic drugs. The company focuses primarily on addressing unmet clinical needs within the specialized field of wound healing and tissue repair. Its core product strategy centers on platelet-derived growth factor (PDGF) drugs, aimed at treating patients with chronic and acute wounds globally. B&K maintains a diversified pipeline of candidate products. Key clinical assets include Pro-101-1, developed for treating deep and superficial second-degree burns/scalds (having completed Phase IIb statistical analysis), and Pro-101-2, currently in Phase II clinical trials for the treatment of Diabetic Foot Ulcers (DFU).

Recent filings

Filing Released Lang Actions
PROPOSED CHANGE OF THE CHINESE NAME OF THE COMPANY AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
Regulatory Filings Classification · 1% confidence The document is a stock exchange announcement detailing the board’s proposal to change the company’s Chinese name and amend its articles of association, outlining resolutions to be tabled at a general meeting. It does not constitute an investor presentation, financial report, proxy statement, or voting results, nor does it announce a dividend, capital raise, or M&A transaction. Hence, it falls into the residual category for regulatory announcements that do not fit other specific filing types.
2026-04-29 English
Environmental, Social & Governance Report 2025
Regulatory Filings
2026-04-29 English
Annual Report 2025
Regulatory Filings
2026-04-29 English
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND PROPOSED ABOLITION OF THE SUPERVISORY COMMITTEE
Regulatory Filings
2026-04-17 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2026
Regulatory Filings Classification · 1% confidence The document is titled “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules” and is a periodic statutory filing to HKEX detailing movements in registered share capital, issued shares, public float confirmations, and related confirmations under listing rules. It is not announcing a specific corporate action like a share issue (no changes occurred) nor presenting a full annual or interim report. Therefore it is best classified as a general regulatory filing.
2026-04-09 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 1% confidence The document is a preliminary annual results announcement filed with the Hong Kong Exchange, titled “Annual Results Announcement for the Year Ended 31 December 2025.” It contains consolidated financial highlights, detailed statements of profit or loss, statements of financial position, and notes prepared under Listing Rule disclosure requirements. It is not the full formal annual report (10-K) nor a notice simply stating a report is available; rather, it is the initial public release of annual financial results. This matches the definition of an Earnings Release (ER). FY 2025
2026-03-30 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.